Statin use and incident prostate cancer risk: Does the statin brand matter? A population-based cohort study

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 6-9

  Lustman, A ^a,b   Nakar, S ^a,b   Cohen, A D ^b,c   Vinker, S ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; COHORT ANALYSIS; HEALTH SURVEY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84894069158     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.34     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-519.
3. Blanco-Colio LM, Villa A, Ortego M, Hernández-Presa MA, Pascual A, Plaza JJ et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26.
4. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-19.
5. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLJ. Statins and prostate cancer prevention: where are we now and future directions. Nat Clin Pract Urol 2008;5:376-387.
6. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-260.
7. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:2226-2232.
8. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U. S. cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2213-2217.
9. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-2368.
10. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
11. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825.
12. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-325.
13. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al. Statin use and risk of prostate cancer in the California men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-2225.
14. Singal R, Khurana V, Caldito G, Fort C. Statins and prostate cancer risk: a large case-control study in veterans. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings, Alexandria, VA. 2005;23:1004.
15. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-2394.
16. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the west of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486.
17. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-2192.
18. Kaiserman N, Vinker S, Kaiserman I. Statins do not decrease the risk for wet agerelated macular degeneration. Curr Eye Res 2009;34:304-310.
19. Kaiserman I, Kaiserman N, Elhayany A, Vinker S. Topical beta-blockers are not associated with an increased risk of treatment for depression. Ophthalmology 2006;113:1077-1080.
20. Merzon E, Weiss NS, Lustman AJ, Elhayani A, Dresner J, Vinker S. Statin administration and risk of cholecystectomy: a population-based case-control study. Exp Opin Drug Safety 2010;9:539-543.
21. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001;3:404-408.
22. World Health Organization. ATC/DDD index database. Available from http://www.whocc.no/atc-ddd-index/.
23. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001;22:1727-1731.
24. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-968.
25. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-2316.
26. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 2008;372:356-361.
27. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trend Pharmacol Sci 1998;19:26-37.
28. Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010;127:1650-1659.